Article
Design of Experiments in CMC — DOE Methodology for Process Characterization and the Regulatory Submission
Design of Experiments is the foundation of modern pharmaceutical process characterization, and every CMC team running DOE studies for a design space submission believes their methodology is sound.…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Design of Experiments in CMC — DOE Methodology for Process Characterization and the Regulatory Submission
Design of Experiments is the foundation of modern pharmaceutical process characterization, and every CMC team running DOE studies for a design space submission believes their methodology is sound.…
Article
ICH Q9(R1) Quality Risk Management — The Updated Annex I and What Changed for CMC Risk Assessment Teams
The original ICH Q9(R1) guideline for quality risk management was issued in 2005. The pharmaceutical industry adopted FMEA as the standard QRM tool, built risk assessments into CMC…
Article
Manufacturing Intelligence Platforms — Pharma 4.0 and the CMC Data Architecture for Regulatory Defense
Pharmaceutical manufacturing has invested heavily in Pharma 4.0: process historians capturing millions of data points per batch, manufacturing execution systems tracking every material movement and operator action, LIMS…
Article
Predictive Dissolution Modeling — PBPK and In Vitro-In Vivo Correlation Applied to the NDA Submission
Dissolution testing is the most frequently performed analytical test in pharmaceutical quality control. Every oral drug product has a dissolution specification. But for modified-release oral drug products —…
Article
Digital Manufacturing and Electronic Batch Records — FDA EBR Expectations and the cGMP Compliance Framework
The pharmaceutical industry has been implementing electronic batch records for more than two decades. 21 CFR Part 11 was issued in 1997. FDA's predicate rule for batch records…
Article
Model-Based Process Development — First-Principles and Hybrid Models in CMC Regulatory Submissions
Mechanistic and hybrid process models are now routine in pharmaceutical process development — population balance models for granulation and crystallization, computational fluid dynamics for mixing scale-up, first-principles droplet…
Article
Statistical Process Control in GMP — SPC Implementation That Satisfies FDA 21 CFR 211 and ISO Requirements
Every pharmaceutical quality director knows that Stage 3 Continued Process Verification requires ongoing process monitoring using statistical methods — FDA's 2011 Process Validation Guidance says this explicitly. And…
Article
Parametric Release and RTRT for Terminally Sterilized Products — The FDA Regulatory Framework
The compendial sterility test carries well-documented sensitivity limitations: with the standard sample size drawn from a batch, a lot with a very low contamination rate has only a…
Article
Quality by Design for Biologics — Design Space, MVDA, and the BLA Manufacturing Section Architecture
ICH Q8(R2) was finalized in 2009. ICH Q11 was published in 2012. Fifteen-plus years of regulatory infrastructure for Quality by Design, and the biologics BLA failure mode for…
Article
PAT for Continuous Manufacturing — In-Line, At-Line, and On-Line Analytics in the Regulatory CMC Submission
Process Analytical Technology has been an FDA regulatory priority since 2004. The PAT guidance was published two decades ago. ICH Q8, Q10, and Q13 all reference PAT as…
Article
Continuous Bioprocessing — Perfusion Culture and Continuous Chromatography CMC Integration in BLA Submissions
Continuous bioprocessing delivers higher volumetric productivity than fed-batch, a smaller facility footprint, and improved quality attribute consistency from steady-state operation. The biopharmaceutical industry knows this. FDA's biologics reviewers…
Article
Continuous Manufacturing for Oral Solid Dosage — ICH Q13 Implementation and the CMC Submission Package
ICH Q13 was finalized in 2022. FDA issued its implementation guidance in 2023. The Emerging Technology Program has been accepting continuous manufacturing applicants for over a decade. And…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.